Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BAY3563254 |
Synonyms | |
Therapy Description |
BAY3563254 comprises a PSMA inhibitor linked to the radionuclide Actinium-225, with an albumin domain for increased tumor uptake and a chelator for stable radiolabeling, which delivers radiation to PSMA-expressing tumor cells, potentially inhibiting tumor growth (Cancer Res (2024) 84 (7_Supplement): ND09). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAY3563254 | BAY 3563254|225Ac-PSMA-Trillium | BAY3563254 comprises a PSMA inhibitor linked to the radionuclide Actinium-225, with an albumin domain for increased tumor uptake and a chelator for stable radiolabeling, which delivers radiation to PSMA-expressing tumor cells, potentially inhibiting tumor growth (Cancer Res (2024) 84 (7_Supplement): ND09). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06217822 | Phase I | BAY3563254 | First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (PAnTHA) | Recruiting | GBR | CAN | BEL | 0 |